The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, organised a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 in Haridwar to promote awareness of pharmacopoeial standards and strengthen quality compliance in the pharmaceutical sector.
The conclave, organised in collaboration with the Association of Devbhumi Pharma Industries (ADPI) and affiliated pharmaceutical manufacturing associations of Uttarakhand, focused on the theme “Strengthening Pharmaceutical Manufacturing through Pharmacopoeial Standards and Quality Compliance.”
According to an official statement, the initiative aimed to familiarise pharmaceutical manufacturers and other stakeholders with the provisions of IP 2026 and encourage wider adoption of quality standards across the industry.
Uttarakhand, one of the country’s major pharmaceutical manufacturing hubs, was chosen as the venue in view of its significant contribution to medicine production and its extensive use of Indian Pharmacopoeia standards and reference substances for ensuring the quality, safety and efficacy of medicines.
The programme brought together representatives from pharmaceutical manufacturing units, quality assurance and quality control professionals, regulatory authorities, analytical scientists and personnel from drug testing laboratories to discuss recent developments in pharmacopoeial standards and their implementation.
Addressing the inaugural session, ADPI Chairman Sandeep Jain highlighted the importance of collaboration between industry and standard-setting institutions in strengthening pharmaceutical quality systems.
Assistant Drugs Controller (India), CDSCO, Dehradun, Sidharth Sahai Malhotra, and Uttarakhand Drug Controller and State Licensing Authority Tajber Singh also addressed the gathering and stressed the role of pharmacopoeial standards in ensuring regulatory compliance and protecting public health.
Delivering the keynote address, IPC Secretary-cum-Scientific Director Dr. V. Kalaiselvan underlined the role of the Indian Pharmacopoeia in establishing scientifically validated standards for medicines. He highlighted key advancements incorporated in IP 2026 and called for active industry participation in implementing the updated standards.
The conclave featured technical sessions on recent developments in pharmacopoeial standards, reference substances, microbiological quality requirements, quality management systems, analytical investigations and biological standards. Participants were provided practical insights into the application of these standards in pharmaceutical manufacturing and quality control processes.
An interactive session enabled industry representatives to engage directly with IPC scientists and seek clarifications on technical, regulatory and implementation-related aspects of IP 2026.
According to the organisers, the discussions reflected growing industry interest in understanding evolving pharmacopoeial requirements and adopting best practices to strengthen quality assurance mechanisms.
